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Abstract 
Background: Neuropathic pain is a clinically relevant adverse effect of several anticancer drugs that markedly 
impairs patients’ quality of life and frequently leads to dose reduction or therapy discontinuation. The poor knowl-
edge about the mechanisms involved in neuropathy development and pain chronicization, and the lack of effective 
therapies, make treatment of chemotherapy-induced neuropathic pain an unmet medical need. In this context, the 
vascular endothelial growth factor A (VEGF-A) has emerged as a candidate neuropathy hallmark and its decrease has 
been related to pain relief. In the present study, we have investigated the role of VEGF-A and its receptors, VEGFR-1 
and VEGFR-2, in pain signalling and in chemotherapy-induced neuropathy establishment as well as the therapeutic 
potential of receptor blockade in the management of pain.
Methods: Behavioural and electrophysiological analyses were performed in an in vivo murine model, by using selec-
tive receptor agonists, blocking monoclonal antibodies or siRNA-mediated silencing of VEGF-A and VEGFRs. Expres-
sion of VEGF-A and VEGFR-1 in astrocytes and neurons was detected by immunofluorescence staining and confocal 
microscopy analysis.
Results: In mice, the intrathecal infusion of VEGF-A  (VEGF165 isoforms) induced a dose-dependent noxious hyper-
sensitivity and this effect was mediated by VEGFR-1. Consistently, electrophysiological studies indicated that VEGF-A 
strongly stimulated the spinal nociceptive neurons activity through VEGFR-1. In the dorsal horn of the spinal cord of 
animals affected by oxaliplatin-induced neuropathy, VEGF-A expression was increased in astrocytes while VEGFR-1 
was mainly detected in neurons, suggesting a VEGF-A/VEGFR-1-mediated astrocyte-neuron cross-talk in neuro-
pathic pain pathophysiology. Accordingly, the selective knockdown of astrocytic VEGF-A by intraspinal injection of 
shRNAmir blocked the development of oxaliplatin-induced neuropathic hyperalgesia and allodynia. Interestingly, 
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Background
The neurotoxic effects of anticancer chemotherapy 
induce a clinically relevant neuropathy (chemother-
apy-induced neuropathy, CIN) that markedly impairs 
patients’ quality of life and frequently leads to dose 
reduction or therapy discontinuation. CIN continues 
after therapy withdrawal and beyond cancer resolution 
[1–3]; it is typically associated with neuropathic hyper-
sensitivity deriving from a direct nervous tissue damage 
and the maladaptive response of both peripheral and 
central nervous system.
Studying the role of stem cells in relieving CIN, we 
recently highlighted an increase in plasma concen-
tration of the vascular endothelial growth factor A 
(VEGF-A) in rats repeatedly administered with oxalipl-
atin. Stem cells were able to control pain and normal-
ize VEGF-A suggesting the possible implication of this 
growth factor in neuropathy development [4]. However, 
the role of VEGF-A in pain signalling is debated as con-
flicting literature data suggest both algesic [5–8] and 
analgesic effects [9–13].
VEGF-A is an anti-parallel homodimeric protein that 
belongs to the “Cys-loop” superfamily of proteins. It 
is mainly known as a pro-angiogenic factor mediating 
blood vessel formation, vascular permeability, endothe-
lial cell proliferation, differentiation, leakage, migra-
tion, survival, and motility [14]. Alternative splicing of 
the Vegfa gene selectively removes intron regions and 
joins specific combinations of exons to generate dis-
tinct VEGF-A isoforms, designated as  VEGFxxx, where 
xxx represents the number of amino acids present in 
the final protein sequence (i.e.,  VEGF111,  VEGF121, 
 VEGF145,  VEGF165, which is the most commonly rep-
resented isoform,  VEGF189, or  VEGF206) [15]. A major 
site of alternative splicing occurs at exon 8, whereby 
proximal and distal splicing generates the  VEGFxxxa 
(pro-angiogenic) and the  VEGFxxxb (anti-angiogenic) 
isoforms, respectively [12, 15, 16]. Interestingly, in qui-
escent vessels the highest proportion of total VEGF-
A is represented by  VEGF165b [17]. Although the 
relevance of  VEGF165b in physiopathological processes 
is controversial [18], several recent studies demonstrate 
the splicing mechanisms leading to  VEGF165b genera-
tion [19] and its involvement in immunomodulation, 
retinopathies and cancer [20–22].
From an evolutionary perspective, VEGF-A emerged 
in the CNS of primitive organisms that lacked an estab-
lished vasculature, suggesting a vessel-independent activ-
ity [23, 24]. Indeed, growing evidence indicates a diverse 
range of effects of VEGF-A on neural cells during devel-
opment and in adulthood [23, 25]. In particular, it pro-
motes CNS perfusion and induces direct neurotrophic 
effects in normal and pathological conditions and, as a 
permeability factor, VEGF-A modulates the blood-brain-
barrier (BBB) functionality [26, 27].
The production of VEGF-A is mainly regulated by 
hypoxia via the hypoxia inducible factor and by sev-
eral growth factors (including the epidermal and the 
platelet-derived growth factors), as well as by oncogenic 
mutations (VHL, RAS, WNT, KRAS signalling pathway 
genes) (reviewed in [28]). Cellular responses to VEGF-A 
are mainly driven by their cognate receptors, VEGFR-1-
and-2, belonging to the class IV receptor tyrosine kinase 
family [29]. The well-known VEGFR-2 plays essential 
roles in physiological angiogenesis [30] and mediates 
the neuroprotective effects of VEGF-A [10, 31]. Con-
versely, VEGFR-1 has been associated with pathological 
processes such has inflammation and tumour-associated 
angiogenesis [32]. This receptor has a higher affinity for 
VEGF-A than VEGFR-2 and is widely expressed also in 
non-endothelial cells [15] (see [29] for a review about the 
physiological roles of VEGF-A mediated by its receptors).
We have recently generated an anti-VEGFR-1 mAb 
(D16F7) that has shown antitumor activity in orthotopic 
in vivo models of highly aggressive cancers such as mela-
noma and glioblastoma [33–35]. The VEGF-A recep-
tor VEGFR-1 has been shown to be expressed in several 
components of the tumour microenvironment, besides 
tumour cells themselves: tumour infiltrating endothelial 
cells, and tumour-associated macrophages of the pro-
tumour M2 phenotype, whose precursors are mobilized 
from the bone marrow and recruited to the tumour site 
both intrathecal and systemic administration of the novel anti-VEGFR-1 monoclonal antibody D16F7, endowed with 
anti-angiogenic and antitumor properties, reverted oxaliplatin-induced neuropathic pain. Besides, D16F7 effectively 
relieved hypersensitivity induced by other neurotoxic chemotherapeutic agents, such as paclitaxel and vincristine.
Conclusions: These data strongly support the role of the VEGF-A/VEGFR-1 system in mediating chemotherapy-
induced neuropathic pain at the central nervous system level. Thus, treatment with the anti-VEGFR-1 mAb D16F7, 
besides exerting antitumor activity, might result in the additional advantage of attenuating neuropathic pain when 
combined with neurotoxic anticancer agents.
Keywords: VEGF-A, VEGFR-1, Neuropathy biomarker, Astrocytes, D16F7 mAb, Oxaliplatin, Vincristine, Paclitaxel, 
Melanoma
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through VEGFR-1 activation by specific ligands. In this 
context, blockade of VEGFR-1 by D16F7 results in: a) 
inhibition of tumour-associated angiogenesis; b) reduc-
tion of myeloid progenitor mobilization and tumour 
infiltration by M2 macrophages/microglia; c) increase 
the CD8/Tregs lymphocytes ratio within the tumour; d) 
inhibition of invasiveness and vasculogenic mimicry of 
VEGFR-1 positive tumour cells [33, 35, 36].
The present work dissects the pain modulatory prop-
erties of VEGF-A at the CNS level in physiological and 
neuropathic conditions using preclinical in  vivo models 
of CIN. Moreover, the role of the different receptor sub-
types in pain signalling and the impact of targeting the 
VEGF-A/VEGFRs system in pain relief were explored. 
Our findings indicate the direct involvement of VEGF-A/
VEGFR-1 in mediating chemotherapy-induced neuro-
pathic pain at the CNS level and the therapeutic poten-




Eight weeks old male CD-1 mice (Envigo, Varese, Italy) 
weighing 20–25 g at the beginning of the experimental 
procedure were used. Animals were housed in the “Cen-
tro Stabulazione Animali da Laboratorio” (University of 
Florence, Italy) and in “Stabulario Centralizzato di Ate-
neo” (University of Campania “Luigi Vanvitelli”, Naples, 
Italy) and used at least 1 week after their arrival. Mice 
were housed in cages measuring 26 cm × 41 cm; animals 
were fed with a standard laboratory diet and tap water 
ad  libitum and kept at 23 ± 1 °C with a 12 h light/dark 
cycle (light at 7 am).
Treatments
VEGF165b (cat. #3045-VE-025, R&D System, USA), 
PlGF-2 (cat. 465-PL/CF, R&D System, USA), VEGF-
E (cat. #CYT-263, Prospec, Israel), D16F7 [33] and 
DC101 (catalogue #BE0060 BioCell, Boston, MA, USA) 
or vehicle (0.9% NaCl) were injected intrathecally (i.t.) 
in conscious mice at the indicated doses in 5 μl, as pre-
viously described [37]. Briefly, a 25-μl Hamilton syringe 
connected to a 30-gauge needle was intervertebrally 
inserted between the L4 and L5 region, and advanced 
6 mm into the lumbar enlargement of the spinal cord. 
Behavioural measurements were performed before and 
30 min, 1 h, 3 h and 6 h after the administration of com-
pounds. DC101 or D16F7 were injected 15 min before 
the VEGFR-1/2 agonists when administered in the co-
treatment experiments.
The scrambled siRNA or the specific VEGFR siRNA 
(VEGFR-1 or VEGFR-2 siRNA, Ambion Life Technolo-
gies, Monza, Italy) were i.t. injected twice spaced 24 h 
apart (3.3 μg/5 μl per mouse) at the lumbar level of the 
mice spinal cord. On the third day, behavioural meas-
urements were conducted after administration of VEG-
FRs agonists. Mice were sacrificed between days 4th and 
5th for western blot analysis. Target sequences of the 
anti-mouse VEGFRs siRNAs were as follows: VEGFR-
1, sense strand 5′-GCA UCU AUA AGG CAG CGG Att-3′ 
and antisense strand UCC GCU GCC UUA UAG AUG Ctc-
3′; VEGFR-2, sense strand 5′-CCC GUA UGC UUG UAA 
AGA Att-3′ and antisense strand 5′-UUC UUU ACA AGC 
AUA CGG Gct-3′.
Adeno‑associated virus (AAV) infection
A shRNAmir vector specific for mouse VEGF-A, labelled 
with green fluorescent protein (GFP) and containing a 
glial fibrillary acidic protein (GFAP) promoter (AAV1-
GFAP-eGFP-mVEGFA-shRNAmir, 1.6 X 1013 GC/ml, 
Vector Biosystem Inc., Malvern, PA, USA), or a vector 
containing a scrambled version of VEGF-A were used. 
Mice were deeply anaesthetized by intraperitoneal (i.p.) 
injection of ketamine (100 mg  kg− 1) (Ketavet, MSD Ani-
mal Health, Milan, Italy) and xylazine (10 mg  kg− 1) (Rom-
pum, 20 mg/ml, Bayer, Milan, Italy) and then were placed 
in a stereotaxic frame using the mouse spinal adaptor 
(Stoelting, Wood Dale, IL, USA). The skin was incised 
at Th12-L5 and the mouse muscles around the left side 
of the interspace between Th12-L1 and L4-L5 vertebrae 
were removed. The dura mater and the arachnoid mem-
brane were then carefully incised using the tip of a 30G 
needle to allow vector infusion through a small window. 
Intraspinal injections were done using a 5-μl Hamil-
ton syringe connected to a 34G needle. The needle was 
placed 0.5 mm lateral to the spinal midline at a depth of 
0.4 mm from the dorsal surface of the spinal cord and 1 μl 
of VEGF-A shRNAmir or scrambled vectors was bilater-
ally injected at 0.25 μl/min with a digital microinjector 
(Stoelting). The needle was left on place for another 3 min 
to prevent backflow. The surgical site was then sutured 
with 3–0 silk and mice were kept on a heating pad until 
recovery.
CIN in vivo models
In mice treated with oxaliplatin (Carbosynth, Pang-
bourne, UK; 2.4 mg  kg− 1) the drug was administered i.p. 
for 2 weeks [38, 39]. Oxaliplatin was dissolved in a 5% 
glucose solution. Control animals received an equivalent 
volume of vehicle. Behavioural tests were performed on 
day 15 for the acute treatments. In mice injected spinally 
with the VEGF-A shRNAmir vector or with the cor-
responding scrambled vector, oxaliplatin was adminis-
tered for 2 weeks (10 total injections), starting treatment 
14  days after viral vector administration. Control animals 
received an equivalent volume of vehicle. Behavioural 
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measurements were performed on days 3, 5, 9, 11, 13 and 
15.
Mice treated with paclitaxel (Carbosynth; 
2.0 mg  kg− 1) were injected i.p. on four alternate days 
(days 1, 3, 5 and 8) [39, 40]. Paclitaxel was dissolved 
in a mixture of 10% saline solution and Cremophor 
EL, a derivative of castor oil and ethylene oxide that 
is clinically used as paclitaxel vehicle. Control animals 
received an equivalent volume of vehicle and behav-
ioural measurements started on day 10.
Mice treated with vincristine (Carbosynth; 0.1 mg  kg− 1) 
were injected i.p. for five consecutive days [41]. Vincris-
tine was dissolved in saline solution and control animals 
received an equivalent volume of vehicle. Behavioural 
measurements started on day 8.
Assessment of mechanical hyperalgesia (Paw pressure test)
Mechanical hyperalgesia was determined by measur-
ing the latency in seconds to withdraw the paw away 
from a constant mechanical pressure exerted onto the 
dorsal surface [42, 43]. A 15 g calibrated glass cylindri-
cal rod (10 mm diameter) chamfered to a conical point 
(3 mm diameter) was used to exert the mechanical force. 
The weight was suspended vertically between two rings 
attached to a stand and was free to move vertically. A sin-
gle measure was made per animal and a cut-off time of 
40 s was used.
Assessment of thermal allodynia (Cold plate test)
Thermal allodynia was assessed using the Cold-plate test. 
With minimal animal-handler interaction, mice were 
taken from home-cages, and placed onto the surface of 
the cold-plate (Ugo Basile, Varese, Italy), maintained at 
a constant temperature of 4 °C ± 1 °C. Ambulation was 
restricted by a cylindrical Plexiglas chamber (diameter: 
10 cm, height: 15 cm), with open top. A timer controlled 
by foot peddle began timing response latency from the 
moment the mouse was placed onto the cold-plate. Pain-
related behaviour (licking of the hind paw) was observed, 
and the time (seconds) of the first sign was recorded. The 
cut-off time of the latency of paw lifting or licking was set 
at 30 s [44].
Assessment of mechanical allodynia (von Frey test)
Mechanical allodynia was measured with the dynamic 
plantar aesthesiometer (von Frey instrument) (Ugo 
Basile), as described by Di Cesare Mannelli and col-
leagues [39] with minor modifications. Briefly, the 
mice were placed in individual Plexiglas cubicles 
(8.5 × 3.4 × 3.4 cm) on a wire mesh platform. After 
approximately 30 min accommodation period, dur-
ing which exploratory and grooming activity ended, the 
mechanical paw withdrawal threshold was measured 
as the hind paw withdrawal responded to von Frey hair 
stimulation. The mechanical stimulus was delivered to 
the plantar surface of the mouse hind paw from below the 
floor of the test chamber by an automated testing device. 
A steel rod (2 mm) was pushed with electronic ascending 
force (0–5 g in 35 s). When the animal withdrew its hind 
paw, the mechanical stimulus was automatically with-
drawn, and the force recorded to the nearest 0.1 g. Nocic-
eptive response for mechanical sensitivity was expressed 
as mechanical withdrawal threshold in grams. The mean 
was calculated from six consecutive trials and averaged 
for each group of mice.
Assessment of locomotor activity (Hole‑board test)
The locomotor activity was evaluated by using the hole-
board test. The apparatus consisted of a 40 cm square 
plane with 16 flush mounted cylindrical holes (3 cm 
diameter) distributed 4 × 4 in an equidistant, grid-like 
manner. Mice were placed on the centre of the board one 
by one and allowed to move about freely for a period of 
5 min each. Two photobeams, crossing the plane from 
mid-point to mid-point of opposite sides, thus dividing 
the plane into 4 equal quadrants, automatically signalled 
the movement of the animal (counts in 5 min) on the sur-
face of the plane (locomotor activity). Miniature photo-
electric cells, in each of the 16 holes, recorded (counts in 
5 min) the exploration of the holes (exploratory activity) 
by the mice [45].
Electrophysiological recordings of nociceptive specific (NS) 
neurons
On the day of electrophysiological recordings, mice 
were initially anesthetized with tribromoethanol (Aver-
tin, Winthrop laboratories, New York, NY, USA; 1.25%). 
After tracheal cannulation, a catheter was placed into the 
right external jugular vein, to allow continuous infusion 
of propofol (5–10 mg/kg/h, i.v.) and spinal cord segments 
L4-L6 were exposed by laminectomy, near the dorsal root 
entry zone, up to a depth of 1 mm [46]. An elliptic rub-
ber ring (about 3 × 5 mm), sealed with silicone gel onto 
the surface of the cord, was used for topical spinal drug 
application and to gain access to spinal neurons. Animals 
were fixed in a stereotaxic apparatus (David Kopf Instru-
ments, Tujunga, CA, USA) through clamps attached to 
the vertebral processes. Single unit extracellular activ-
ity of dorsal horn NS neurons was performed by using 
a glass-insulated tungsten filament electrode (3–5 MΩ) 
(FHC Frederick Haer & Co., ME, USA). Spinal neurons 
were defined as NS neurons, when they were respond-
ing only to high intensity (noxious) stimulation [47]. In 
particular, to confirm NS response patterns, each neuron 
was characterized by applying a mechanical stimulation 
to the ipsilateral hind paw using a von Frey filament with 
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97.8 mN bending force (noxious stimulation) for 2 s until 
it buckled slightly [48, 49]. Only neurons that specifically 
responded to noxious hind paw stimulation were consid-
ered for recordings. The recorded signals were visualized 
into a window discriminator, whose output was pro-
cessed by an interface CED 1401 (Cambridge Electronic 
Design Ltd., UK) connected to iOS 5 PC. Spike2 soft-
ware (CED, version 5) was used to create peristimulus 
rate histograms on-line and to store and analyse digital 
records of single unit activity off-line. The spontaneous 
and noxious-evoked neuronal activity was expressed as 
spikes/sec (Hz) and the effect of drugs was analysed as % 
variation of firing rate, frequency and duration of excita-
tion. After recording a stable basal activity (15 min), topi-
cal spinal application of vehicle or drugs was performed, 
and each extracellular recording was monitored until 
45–60 min post-injection. In particular, groups of ani-
mals were divided as follows: 1)  VEGF165b (3 ng/5 μl, pro-
nociceptive dose on NS neurons), 2)  VEGF165b + DC101 
(10 pg/5 μl, the highest non pro-nociceptive dose) and 3) 
 VEGF165b + D16F7 (100 pg/5 μl). At the end of the experi-
ment, animals were killed with a lethal dose of urethane.
Western blot analysis
The lumbar spinal cord of mice was explanted and imme-
diately frozen with liquid nitrogen. The frozen tissues 
were homogenized with lysis buffer containing 50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% Tri-
ton X-100 and complete protease inhibitors (Roche, 
Milan, Italy). The suspensions were sonicated on ice using 
three high intensity 10s bursts with a cooling period of 
10s each burst and centrifuged at 13,000×g for 10 min 
at 4 °C. Protein concentrations were quantified by bicin-
choninic acid test. Fifty μg of tissue homogenate were 
resolved with precast polyacrylamide gel (BOLT 4–12% 
Bis-Tris Plus gel; Thermo Fisher Scientific, Monza, Italy) 
before electrophoretic transfer to nitrocellulose mem-
branes (Bio-Rad, Milan, Italy). The membranes were 
blocked with 1% BSA and 5% fat-free powdered milk in 
PBS containing 0.1% Tween 20 (PBST) and then probed 
overnight at 4 °C with primary antibodies specific for 
VEGFR-1, VEGFR-2, VEGF-A, GAPDH or α-tubulin 
(Table S1). The membranes were then incubated for 1 h 
in PBST containing the appropriate secondary anti-rab-
bit or anti-mouse antibody (Table S1). ECL (Enhanced 
Chemiluminescence Pierce, Rockford, IL, USA) was used 
to visualize peroxidase-coated bands. Densitometric 
analysis was performed using the ImageJ analysis soft-
ware (ImageJ, NIH, Bethesda, MD, USA). Normalization 
for α-tubulin or GAPDH content was performed. The 
values were reported as percentages of controls arbitrar-
ily set at 100%.
Immunofluorescence staining and confocal imaging
After animal sacrifice, the L4-L5 segments of the 
spinal cord were exposed from the lumboverte-
bral column via laminectomy and identified by trac-
ing the dorsal roots from their respective dorsal root 
ganglion. Formalin-fixed (and no-fixed, used for 
VEGFR-1 primary antibody) cryostat sections (7 μm) 
were washed 3x with phosphate-buffered saline 
(PBS) and then incubated, at room temperature for 
1 h, in blocking solution (PBS, 0.3% Triton X-100, 
5% albumin bovine serum; PBST). The sections were 
subsequently incubated with the anti-VEGFR-1, anti-
VEGF-A, or anti-Aquaporin 4 (anti-AQP-4) (a marker 
of astrocytic endfeet) primary antibodies, overnight at 
4 °C (Table S1). The following day, slides were washed 
3× with PBS and then sections were incubated in the 
dark with goat anti-rabbit or anti-mouse IgG second-
ary antibodies labelled with Alexa Fluor 568, in PBST 
at room temperature for 2 h. After 3× PBS 0.3% Triton 
X-100 wash for 10 min, the sections were incubated 
with DAPI, as nuclear marker, at room temperature 
for 5 min and then the slides were mounted using 
Fluoromount™ (Life Technologies-Thermo scientific, 
Rockford, IL, USA).
For double immunofluorescence, on the first day, 
an anti-Iba-1 antibody was added and the slides were 
incubated overnight at 4 °C. Conversely, the sections 
to be labelled for GFAP or NeuN were incubated the 
second day for 2 h in the dark with mouse anti-GFAP 
Alexa Fluor 488-conjugated or mouse anti-NeuN Alexa 
Fluor 488-conjugated antibodies (Table S1). For triple 
immunofluorescence, on the first day, an anti-RECA-1 
antibody was added and the slides incubated overnight 
at 4 °C; then, sections were incubated with the anti-
mouse IgG labelled with Alexa Fluor 568 for 2 h. There-
after, incubation with anti-VEGF-A and anti-GFAP 
antibodies was allowed overnight in the dark. Finally, 
anti-mouse IgG labelled with Alexa Fluor 488 and anti-
rabbit IgG labelled with Alexa Fluor 647 were added for 
2 h in the dark (Table S1).
Negative control sections (no exposure to the pri-
mary antisera) were processed concurrently with the 
other sections for all immunohistochemical studies. 
Images were acquired using a motorized Leica DM6000 
B microscope equipped with a DFC350FX camera 
(Leica, Mannheim, Germany).
The colocalization area was calculated using the 
“colocalization” plugin of ImageJ (after evaluating the 
threshold value for each channel) and expressed as per-
centage relative to the value of the VEGFR-1 or VEGF-
A area. The mean fluorescence intensity of VEGF-A, in 
control and oxaliplatin-treated animals, was calculated 
by subtracting the background (multiplied by the total 
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area) from the VEGF-A integrated intensity. Analyses 
were performed on three different images for each ani-
mal, collected through a 20x objective.
For confocal analysis, images were acquired with a 
Leica SP2 AOBS confocal microscope using a sequential 
scan setting (exciting lasers 488 nm and 561 nm) to avoid 
channel bleed-through. Images were acquired though 
a 63 × 1.4 NA PL APO objective at voxel size of 232 nm 
(xy) and 121 nm (z).
Confocal images were processed and analysed using 
Fiji [50]. Briefly, images were deconvolved using Decon-
volution Lab2 with a synthetic PSF and ICTM algorithm 
[51]. Colocalization analysis was performed with JACoP 
(Fiji plugin) [52] and manually set thresholds. Colocaliza-
tion parameters were calculated from 8 confocal z-stacks 
for each analysis.
Statistical analysis
Results were expressed as means ± SEM and the analysis 
of variance was performed by ANOVA test. A Bonferro-
ni’s significant difference procedure was used as post-hoc 
comparison. P values less than 0.05 were considered sig-
nificant. Data were analysed using “Origin® 10” software.
Electrophysiological data were analysed through one-
way ANOVA followed by Dunnet’s multiple comparison 
post-hoc test for statistical significance within groups. 
Two-way ANOVA followed by Bonferroni post-hoc 
test, for comparison between groups, was calculated by 
using GraphPad Prism 7.0. The data and statistical analy-
sis comply with the recommendations on experimental 
design and analysis in pharmacology [53]. For all experi-
ments, data were collected by researchers blind to the 
treatments.
Results
Nociceptive effect of VEGFRs selective ligands infused 
intrathecally
To study the spinal impact of VEGF-A signalling modu-
lation on pain threshold in mice, we firstly evaluated the 
effect of  VEGF165b. This VEGF-A isoform was preferred 
since, differently from  VEGF165a, it is able to specifically 
stimulate VEGFR-1 and VEGFR-2 without binding to 
VEGF-A co-receptors that may differentially interfere 
with the activation of the two tyrosine kinase recep-
tors [54–56]. After i.t. administration of  VEGF165b, 
pain sensitivity was measured as latency response to 
Fig. 1 Nociceptive effect of VEGFRs selective ligands infused in spinal cord. The pain threshold was measured by the Cold plate test over time after 
the i.t. injection of the different molecules. Effect of (a)  VEGF165b (n = 7), (b) the VEGFR-1 selective agonist PlGF-2 (n = 5), (c) the VEGFR-2 selective 
agonist VEGF-E (n = 5), (d) the selective anti-VEGFR-1 antibody D16F7 (n = 7) or a murine control IgG (n = 5) and (e) the selective anti-VEGFR-2 
antibody DC101 (n = 5). (f) Effect of DC101 in mice pre-treated (15 min before) with D16F7. Each value represents the mean ± SEM. *P < 0.05 and 
**P < 0.01 vs vehicle-treated animals; °°P < 0.01 vs DC101 6 ng treated animals. The analysis of variance was performed by one-way ANOVA. A 
Bonferroni’s significant difference procedure was used as post-hoc comparison
Page 7 of 19Micheli et al. J Exp Clin Cancer Res          (2021) 40:320  
a cold stimulus (Cold plate test). As shown in Fig.  1a, 
 VEGF165b (3, 10 and 30 ng, in bolus in a total volume of 
5 μl) dose-dependently reduced pain threshold with a 
long-lasting effect starting 30 min after injection; this 
effect completely disappeared only after 6 h, similarly 
to what observed in rats [4]. Comparable dose-depend-
ent nociceptive effects were observed with the other 
 VEGF165 isoform  (VEGF165a) (see Fig. S1). Since VEGF-
A may interact with both VEGFR-1 and VEGFR-2, in 
order to explore the implications of the receptor types 
in pain modulation, we also tested the effect of placen-
tal growth factor 2 (PlGF-2) and VEGF-E, which are spe-
cific VEGFR-1 and VEGFR-2 agonists, respectively [57]. 
As shown in Fig. 1b and c, both PlGF-2 and VEGF-E (3, 
10 and 30 ng, i.t.) significantly reduced the licking latency 
of animals challenged on a cold surface (Cold Plate test), 
even if PlGF-2 showed a profile similar to  VEGF165b while 
VEGF-E exhibited a lower efficacy. Interestingly, the 
selective VEGFR-1 blockade by the anti-VEGFR-1 mAb 
D16F7 (injected i.t.), in the absence of  VEGF165b, did 
not significantly alter pain threshold at microgram dose 
(Fig.  1d). On the contrary, nanogram dose of the anti-
murine VEGFR-2 mAb DC101 (1 and 6 ng, i.t.) induced 
hypersensitivity (Fig.  1e) and this effect was blocked by 
D16F7 mAb (10 and 100 ng; Fig.  1f ). In this test, non-
specific mouse IgG (1 μg), used as control, was inactive. 
These findings suggested that the nociceptive effects 
evoked by  VEGF165 isoforms were the result of VEGFR-1 
stimulation. Furthermore, algesic effects induced by the 
DC101 mAb were likely due to the antibody-dependent 
displacement of the endogenous VEGF-A from VEGFR-
2, thus making it available for binding to VEGFR-1; this 
hypothesis was further demonstrated by the loss of the 
effect when the anti-VEGFR-1 mAb D16F7, was adminis-
tered together with DC101.
Hypersensitivity‑induced by VEGF‑A signalling modulators 
is due to VEGFR‑1 activation
The hypothesis that VEGFR-1 activation is required 
for VEGF-A-mediated nociception was demonstrated 
by crossing the combinations of receptor agonists and 
antagonists. Both selective agonists, PlGF-2 and VEGF-E 
[58–61], share the same binding sites of VEGF-A on the 
corresponding receptors. At variance with DC101 mAb 
which is a competitive antagonist of VEGF-A and VEGF-
E for VEGFR-2 binding [62], D16F7 mAb is a non-com-
petitive antagonist since it interacts with VEGFR-1 at a 
site different from that used by the receptor ligands [32, 
33]. Consistently with our hypothesis, the algesic effects 
of  VEGF165b are blocked by D16F7 mAb (Fig.  2a). A 
similar profile was obtained also for the VEGFR-1 ligand 
PlGF-2 (Fig. 2b) as well as for the VEGFR-2 ligand VEGF-
E (Fig. 2c). DC101 mAb used at the highest non-algesic 
dose (but able to selectively block VEGFR-2) [62] did 
not block the effect of both  VEGF165b and PlGF-2, but 
further exacerbated VEGF-E hypersensitivity (Fig. S2). 
These findings confirmed the pivotal role of VEGFR-1 in 
pain signalling which is directly activated by the selec-
tive agonist PlGF-2 or by the exogenously added (Fig. 2a) 
or endogenously present VEGF-A (Fig.  2c) displaced 
from VEGFR-2. Moreover, the selective knockdown 
of VEGFR-1 or VEGFR-2 by siRNA further validated 
the specificity of the VEGFR-1-mediated mechanism 
(Fig.  2d-f ). Silencing of VEGFR-1 completely blocked 
the effects of  VEGF165b, PlGF-2 and VEGF-E (Fig.  2e), 
whereas silencing of VEGFR-2 did not alter the algesic 
properties of these ligands (Fig. 2f ).
VEGF165b increases the activity of spinal NS neurons 
by VEGFR‑1 activation
To investigate the effect of the spinal application of 
 VEGF165b on the hyperexcitability of spinal NS neurons, 
in vivo electrophysiological experiments were performed. 
The results relate to NS neurons (one cell recorded from 
each animal per treatment) localized at a depth of 0.7–
1.0 mm from the surface of the spinal cord. This cell pop-
ulation was characterized by a mean rate of basal firing of 
0.015 ± 0.002 spikes/sec and only cells showing this pat-
tern were chosen for the experiment. To investigate the 
involvement of the different VEGF-A receptor subtypes, 
spontaneous and noxious-evoked (mechanical stimula-
tion) activity of NS neurons was measured after spinal 
application of  VEGF165b, preceded or not by treatment 
with the anti-VEGFR-1 mAb D16F7. Representative 
ratematers of the results obtained with  VEGF165b in the 
absence or presence of D16F7 mAb are shown in Fig. 3a 
and b, respectively. In mice pre-treated with vehicle (0.9% 
NaCl),  VEGF165b (3 ng/5 μl) spinal application induced an 
increase in spinal electrical activity as compared to base-
line levels (100%). In particular, NS neurons showed a 
variation of spontaneous activity compared to baseline of 
217.05 ± 29.2% as well as a noxious-evoked activity with 
frequency of 234 ± 30.9% and duration of 316.2 ± 27.2%, 
starting from 25 min post  VEGF165b (Fig.  3a, c-e). The 
spinal  VEGF165b-induced hypersensitivity was mainly 
mediated by VEGFR-1 rather than VEGFR-2 activation. 
Indeed, electrophysiological recordings revealed that 
spinal pre-application of D16F7 mAb (100 pg/5 μl) signif-
icantly prevented the increase of spontaneous and nox-
ious-induced activity of NS neurons resulting in a pattern 
similar to baseline (Fig.  3b, c-e). D16F7 (100 pg/5 μl) 
alone was not able to affect either spontaneous or evoked 
activity of NS neurons (Fig. 3b). On the contrary, DC101 
at 30 and 100 pg, showed a pro-nociceptive effect on 
spinal NS neuron activity per se (Fig. S3, representa-
tive ratematers). In fact, post-injection level of either 
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spontaneous (187.3 ± 17.7% at 100 pg and 151.1 ± 6.9% 
at 30 pg) or noxious pressure-evoked firing rates (fre-
quency: 212.6 ± 27% at 100 pg and 152.9 ± 6.9% at 30 pg; 
duration: 235.7 ± 25.3% at 100 pg and 119.7 ± 8.6% at 
30 pg) were significantly higher respect to the baseline, 
in a dose-dependent manner. Overall, these results fur-
ther confirmed the involvement of VEGFR-1 in VEGF-A-
induced electrophysiological changes of NS neurons.
VEGF‑A and VEGFR‑1 localization in the spinal cord of naïve 
mice
Immunofluorescence analysis was performed in the 
dorsal horn of the spinal cord to study VEGF-A and 
VEGFR-1 expression profile in the nerve cells. VEGF-A 
immunoreactivity in astrocytes (as colocalization with 
GFAP; Fig.  4a and d) was significantly higher in com-
parison to microglia (Iba-1 positive cells) and neurons 
(NeuN positive cells) (Fig.  4b, c and d). As expected, 
VEGF-A staining was strictly related to vessel struc-
ture (Fig. 4a, c and d) since its expression was observed 
both on endothelial cells and astrocyte endfeet [25]. To 
better investigate this aspect, we compared the co-local-
ization of VEGF-A with GFAP and RECA-1, a marker of 
endothelial cells (Fig. 5 and Fig. S4). As shown in Fig. 5a, 
it is possible to identify separate areas of VEGF-A/GFAP 
and VEGF-A/RECA-1 colocalization. Furthermore, 
VEGF-A expression in astrocytes was also confirmed 
by confocal microscopy. Results shown in Fig.  5b and c 
confirm the colocalization of VEGF-A with GFAP and 
AQP4. Indeed, the Van Steensel’s cross-correlation func-
tion (CCF) clearly shows that VEGF-A co-localizes with 
GFAP and AQP4 in cellular structures with estimated 
diameters of 1.00 ± 0.11 μm and 1.28 ± 0.12 μm (CCF 
at FWHM, mean ± SD, Fig. S4), respectively, which are 
compatible with the size of astrocytic processes. Col-
lectively, these analyses demonstrate the presence of a 
VEGF-A pool in astrocytes.
VEGFR-1 expression was, instead, more prominent in 
neurons than in astrocytes (Fig. 4e, f and g).
Fig. 2 VEGF-A family members induce hypersensitivity through interaction with VEGFR-1. The response to a thermal stimulus (Cold plate test) was 
recorded after i.t. infusion of different VEGFR ligands (30 ng) preceded (15 min before) or not by the anti-VEGFR-1 mAb D16F7 (100 ng) or vehicle: 
(a)  VEGF165b ± D16F7 (n = 5), (b) PlGF-2 ± D16F7 (n = 5), (c) VEGF-E ± D16F7 (n = 5). (d) Representative western blot images and densitometric 
analysis showing the expression of VEGFR-1 or VEGFR-2 in the lumbar section of the spinal cord after the siRNAs administration (n = 5). (e ‑ f) Effects 
of VEGFR ligands (i.t.) in mice undergone a selective knockdown of VEGFR-1 (e, n = 5) or VEGFR-2 (f, n = 5) at the lumbar level of the spinal cord 
by siRNA. Each value represents the mean ± SEM. **P < 0.01 vs vehicle + vehicle-treated animals; °°P < 0.01 vs vehicle + VEGFRs ligands-treated 
animals. The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc 
comparison
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VEGF‑A is increased in spinal astrocytes of mice 
with oxaliplatin‑induced neuropathy
A painful neuropathy was reproduced in mice by a 
repeated treatment with oxaliplatin [38, 39]. After 
2 weeks of treatment, when hypersensitivity was 
developed, VEGF-A immunoreactivity significantly 
increased in dorsal horns of the spinal cord in com-
parison to control animals (Fig.  6a and Fig. S5). The 
increment was specifically confirmed in astrocytes 
when colocalization of VEGF-A expression in GFAP-
positive cells was measured (Fig. 6b, c and d). In regard 
to VEGFRs, VEGFR-2 expression increased in the spi-
nal cord of oxaliplatin-treated mice, as revealed by 
western blot; on the contrary VEGFR-1 was unaffected 
by treatment with chemotherapy (Fig. S6).
VEGF‑A silencing in astrocytes prevents neuropathic pain
To analyse the influence of astrocytic VEGF-A modula-
tion on pain signalling, we selectively silenced VEGF-
A in spinal astrocytes by injecting a VEGF-A specific 
AAV-derived shRNAmir targeting glial cells. The vector 
was bilaterally injected at the lumbar and thoracic lev-
els of the spinal cord 2 weeks before the first oxaliplatin 
treatment. As shown in Fig.  7a, 4 weeks after injection, 
the vector fluorescence colocalized with GFAP-positive 
cells inducing a significant decrease of VEGF-A expres-
sion (Fig.  7b). The pain threshold measurements, by 
Fig. 3 VEGF165b increases spontaneous and noxious-evoked activity of NS neurons through VEGFR-1. Representative ratematers showing 
spontaneous and noxious-evoked activity of NS neurons after spinal application of  VEGF165b alone or in combination with D16F7 mAb (a and 
b, respectively); black arrows indicate the noxious stimulation on the mouse hind-paw. Mean ± SEM population data of spinal cord application 
of  VEGF165b (3 ng/5 μl) in the presence of vehicle (0.9% NaCl), or D16F7 (100 pg/5 μl) on firing rate of spontaneous activity (c), frequency (d) and 
duration of evoked activity (e) of NS neurons in CD1 mice. Black arrows indicate vehicle, D16F7 or  VEGF165b spinal application. Each point represents 
the mean of 5 different mice per group (one neuron recorded per each mouse). #P < 0.05, ##P < 0.01 and ###P < 0.001 indicate statistical difference vs 
baseline; *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistical difference vs vehicle +  VEGF165b. One-way ANOVA followed by Dunnet’s multiple 
comparison post-hoc test was performed for statistical significance within groups. Two-way ANOVA followed by Bonferroni post-hoc test was used 
for comparison between groups
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employing thermal (Cold plate test) and mechanical (von 
Frey test) non-noxious stimuli over time, showed a sig-
nificant prevention of hypersensitivity development dur-
ing the 2 weeks of oxaliplatin treatment in the group that 
received the VEGF-A specific shRNAmir in comparison 
to scrambled- and vehicle-treated mice (Fig.  7c and d). 
To verify the lack of neurological and motor alterations 
which could interfere with pain behaviour recordings, the 
motor functionality and exploratory activity of VEGF-A 
shRNAmir and scrambled-treated mice were evaluated 
by the Hole board test. No alterations were highlighted 
Fig. 4 Cellular localization of VEGF-A and VEGFR-1 in the spinal cord of naïve mice. VEGF-A immunoreactivity was analysed in the spinal cord dorsal 
horn of naïve mice. Colocalization with GFAP-positive astrocytes (a, n = 9), Iba-1 positive microglia (b, n = 8) and NeuN-positive neurons (c, n = 7) 
was evaluated and quantified (d). Quantitative analysis (e) of immunofluorescence co-staining of VEGFR-1 in the dorsal horn with GFAP (f, n = 7) or 
NeuN (g, n = 8) positive cells. Scale bar: 100 μm. Each value represents the mean ± SEM. §§P < 0.01 vs VEGF-A + Iba-1 and VEGF-A + NeuN. ^^P < 0.01 
vs VEGFR-1 + GFAP. The analysis of variance was performed by Oone-way ANOVA. A Bonferroni’s significant difference procedure was used as 
post-hoc comparison
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with the exception of a higher exploratory activity on day 
3 of oxaliplatin protocol (Table S2).
The anti VEGFR‑1 mAb D16F7 relieves pain in different 
models of CIN
To investigate the therapeutic role of a pharmacologi-
cal treatment targeting VEGFR-1 in the management 
of neuropathic pain induced by anticancer drugs, ani-
mals with oxaliplatin-induced neuropathy were treated 
with the anti-VEGFR-1 mAb D16F7. In this model, i.t. 
infusion of D16F7 (100 ng, 1 μg and 5 μg) induced a sig-
nificant, dose-dependent, increase of the pain thresh-
old both after thermal and mechanical non-noxious and 
noxious stimulation. Hypersensitivity was fully counter-
acted (up to control values) from 30 min to 3 h after treat-
ment (Fig. 8a and b). On the contrary, the anti VEGFR-2 
antibody DC101 (100 pg i.t.) was ineffective (Fig. S7). 
Interestingly, D16F7 mAb maintained its efficacy also 
Fig. 5 VEGF-A expression in endothelial and astrocytic cells of murine spinal cord. (a) VEGF-A immunoreactivity was analysed in the spinal cord 
dorsal horn of naïve mice in comparison to RECA-1-positive endothelial cells and GFAP-positive astrocytes; arrows indicate the presence of VEGF-A 
in astrocytes; scale bar: 100 μm. (b and c) Deconvolved confocal z-stacks shown as maximum intensity projection. Arrows indicate points of interest. 
(b) Representative GFAP and VEGF-A z-stack. (c) Representative VEGF-A and aquaporin-4 z-stack. Table). Colocalization parameters are given as 
mean ± SEM (n = 8), PCC = Pearson’s Correlation Coefficient; M1 = Mander’s M1; M2 = Mander’s M2; Li′s ICQ = Li′s Intensity Correlation Quotient. 
Colocalization graphs are shown in Fig. S4
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when systemically injected by the i.p. route (1, 5, 15 and 
25 mg  kg− 1), starting from the dose of 5 mg  kg− 1. The 
onset of the analgesic effect was observed at 60 min, 
and efficacy was maintained up to 120 min (Fig. S8). The 
pain-relieving properties of D16F7 mAb seem not to be 
limited to the oxaliplatin neurotoxicity since it was also 
effective in mice which become hypersensitive after 
treatment with the neurotoxic anticancer drugs vincris-
tine and paclitaxel. In both models, D16F7 mAb (1 and 
5 μg, i.t.) was active between 30 min and 3 h (Fig. 8c-f ) in 
the Cold plate and Paw pressure tests with a particular 
efficacy when the pain response was evoked by thermal 
stimuli (Fig.  8c and e). In paclitaxel-treated mice, 15 μg 
D16F7 mAb dosed i.t. were effective up to 5 h (Fig. 8e).
Discussion
Our data indicate that VEGF-A evokes pain through 
VEGFR-1 activation in physiological and pathological 
conditions. In particular, CIN-related pain is sustained 
by a spinal VEGF-A release from astrocytes and can be 
counteracted by local or systemic administration of the 
Fig. 6 VEGF-A is increased in spinal astrocytes of mice with oxaliplatin-induced neuropathy. (a) Representative images and quantitative analysis 
of mean VEGF-A fluorescence intensity in the dorsal horn of oxaliplatin-treated mice in comparison to control animals (vehicle, n = 13). (b-d) 
Colocalization analysis of VEGF-A and GFAP in control (b) and oxaliplatin-treated mice (c). Quantitative analysis of colocalization area (d) (vehicle, 
n = 13; oxaliplatin, n = 12). Scale bar: 100 μm; insert: 50 μm. Each value represents the mean ± SEM. *P < 0.05 vs vehicle group. The analysis of 
variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
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anti-VEGFR-1 D16F7, a mAb also endowed with anti-
angiogenic and antitumor activity.
Using recombinant  VEGF165b, we showed an increase 
of the electrophysiological activity of nociceptive neu-
rons in the spinal cord with a consequent, significant 
decrease of the pain threshold. These data are in agree-
ment with our previous results [4] and with the periph-
eral pro-nociceptive effect of VEGF-A demonstrated by 
Selvaraj and colleagues [6] after an intraplantar injection 
as well as with the VEGF-A increase in synovial fluid of 
Fig. 7 VEGF-A silencing in astrocytes prevents neuropathic pain. VEGF-A in spinal astrocytes was silenced by injecting in the spinal cord a VEGF-A 
specific AAV-derived shRNAmir targeting glial cells (AAV1-GFAP-eGFP-VEGF-A-shRNAmir). A shRNAmir vector containing a scrambled sequence was 
injected and used as control. (a) Representative images of eGFP and GFAP fluorescence in a whole section at lumbar level, scale bar: 100 μm. Higher 
magnifications were reported to visualize the colocalization, scale bar: 50 μm (n = 4). (b) Representative western blot images and densitometric 
analysis showing the expression of VEGF-A in the lumbar section of the spinal cord after vector administration (n = 4, blot of samples obtained from 
2 animals of each group are shown). Pain threshold was evaluated by (c) Cold plate and (d) Paw pressure tests (n = 5). Each value represents the 
mean ± SEM. *P < 0.05 and **P < 0.01 vs vehicle; ^P < 0.05 and ^^P < 0.01 vs scrambled + oxaliplatin group. The analysis of variance was performed 
by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
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subjects afflicted by osteoarticular pain [7]. Further-
more, in the peripheral nervous system, an anti-VEGF-A 
mAb treatment was found to alleviate neuropathic pain 
induced by the chronic constriction injury of the sciatic 
nerve [5], suggesting an active role of VEGF-A also in the 
peripheral sensitization mechanisms [63]. In our hands, 
both the selective VEGFR-1 agonist PlGF-2 and the 
selective VEGFR-2 agonist VEGF-E induced nociception 
after i.t. infusion. In addition, the selective anti-VEGFR-2 
mAb DC101 induced hypersensitivity whereas the selec-
tive anti-VEGFR-1 mAb D16F7 did not. Based on these 
data, it could be hypothesized that VEGFR-1 selectively 
Fig. 8 D16F7 mAb reduces pain in different models of chemotherapy-induced neuropathy. Effect of D16F7 mAb evaluated by (a) Cold plate 
and (b) Paw pressure tests in a mouse model of oxaliplatin-induced neuropathy after i.t. injection (a, b, n = 6). (c, d) Effect of D16F7 mAb after i.t. 
administration in vincristine-treated mice stimulated with thermal (c) or mechanical (d) stimuli (n = 6). (e, f) Effect of D16F7 after i.t. administration 
in paclitaxel-treated mice stimulated with thermal (e) or mechanical (f) stimuli (n = 6). Each value represents the mean ± SEM. **P < 0.01 vs vehicle 
+ vehicle-treated animals; ^P < 0.05 and ^^P < 0.01 vs chemotherapeutic drugs + vehicle-treated animals. The analysis of variance was performed 
by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post-hoc comparison
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mediates pain, either directly stimulated by exogenously 
PlGF-2 or the endogenously produced VEGF-A displaced 
from VEGFR-2 by VEGF-E or the competitive DC101 
mAb. In this context, it is worth noting that D16F7 mAb 
is a non-competitive inhibitor that hampers VEGFR-1 
activation without affecting ligand binding [32, 33]. The 
involvement of VEGFR-1 in algesia induced by VEGF-
A was confirmed by the ability of D16F7 mAb to block 
the nociceptive effects of all the agonists and of DC101 
mAb. Furthermore, the knockdown of VEGFR-1 pre-
vented  VEGF165b, PlGF-2 and VEGF-E effects, strongly 
supporting the pivotal role of this receptor in the spinal 
pain pathways. These data are in agreement with those 
described by Selvaraj and colleagues [6] in the periph-
eral nervous system where VEGF-A induced nociceptive 
sensitization via VEGFR-1. Consistently with behavioural 
data, electrophysiological experiments revealed that 
 VEGF165b spinal application, caused a marked increase in 
both spontaneous and evoked activity of NS neurons in 
naïve animals. In particular, the increased responsiveness 
to mechanical noxious stimuli of NS neurons induced by 
 VEGF165b spinal microinjection suggests that low doses 
of this compound were able to induce a central sensiti-
sation, similar to the neuropathic pain condition induced 
by nerve injury. In this context, the pre-application of 
D16F7 prevented the VEGF-A-induced neuronal hyper-
excitability, confirming the contribution of this receptor 
in VEGF-A-mediated painful effects.
In the normal healthy CNS, VEGF-A regulates micro-
vascular density, vessel permeability, and maintains 
endothelial cell fenestration in the choroid plexus, 
stimulates neural stem cell proliferation and promotes 
neurogenesis [25]. In pathological conditions (besides 
beneficial vascular effects), it safeguards stressed neu-
rons, induces axon extension and branching, and pro-
motes synaptic plasticity; furthermore, VEGF-A triggers 
proliferation, survival and migration of astrocytes and 
stimulates expression of trophic factors by astrocytes 
and microglia [23, 25]. Glial cells play a crucial role in the 
maladaptive plasticity of the nervous system in chronic 
pain and, particularly, in neuropathies [64]. Activated 
by neuronal damage or by signals from periphery, glia 
participates in pain development and chronicization, 
amplifying the excitatory synaptic microenvironment 
[65, 66]. Released soluble factors, like cytokines and 
growth factors, possess a direct nociceptive effect [67]. 
Among the latter, NGF, BDNF, GDNF, and other fac-
tors, seem unable to separate the neuroprotective effect 
from the algic one, probably following the evolutionary 
positive alarm role of physiological pain [68–70]. In this 
context, the nociceptive effect of VEGF-A is not surpris-
ing. Neuropathies induced by trauma to a peripheral 
nerve [11] or by chemotherapy [4] are characterized by 
enhanced spinal concentration of VEGF-A. The present 
results show, as expected [25], not only a relevant spi-
nal VEGF-A concentration in the vessel structures, but 
also the existence of an extra-endothelial component. 
In comparison to microglia and neurons, astrocytes 
of healthy mice showed the highest amount of VEGF-
A, which was clearly distinguishable from the vascular 
component. The repeated treatment with oxaliplatin up 
to the development of painful neuropathy significantly 
enhanced the presence of the growth factor in astroglia. 
The selective VEGF-A knockdown in dorsal horn astro-
cytes at the lumbar and thoracic levels of the spinal cord 
strongly reduced oxaliplatin-dependent neuropathic pain 
suggesting astrocytic VEGF-A as a relevant component 
of the pain signalling orchestrated by the  glia. Further-
more, enhanced concentrations of VEGF-A can also lead 
to other pathological alterations related to neuropathies 
like an increased BBB permeability [71–73]. In fact, while 
low basal levels of VEGF-A are necessary for the main-
tenance of BBB integrity, high levels of the growth fac-
tor can alter BBB permeability and compromise CNS 
functions [26, 27]. The hypoxia inducible factor-1 driven 
by IL-1 promotes VEGF-A release from astrocytes that 
induces down-regulation or loss of the endothelial tight 
junction proteins claudin-5 and occludin, determining a 
loss of BBB function [26, 74] by mechanisms involving 
VEGFR-1 [8]. On the other hand, the increase in VEGF-
A levels in neurotoxic conditions is generally related to 
hypoxia, as clearly demonstrated in diabetic and chemo-
therapy-induced neuropathies [4, 12, 75], suggesting the 
need of improving vascular functions [25]. The rescue 
role of VEGF-A is also based on its extra-vascular neuro-
protective and neuroregenerative properties mainly due 
to the activation of the VEGFR-2. VEGF-A stimulates the 
migration and survival of Schwann cells [76] and pro-
tects neurons against chemotherapy-induced cytotoxic-
ity via activation of VEGFR-2 and MEK1/2 and inhibition 
of caspase3 [77]. VEGF-A-signalling through VEGFR-2 
leads to the protection of dorsal root ganglion sensory 
neurons in models of drug (paclitaxel) or hyperglycae-
mia-induced neuropathies, through induction of Heat 
Shock Protein 90 deacetylation and increase of Bcl-2 [9, 
10]. The loss of endothelial VEGFR-2 signalling leads 
to tissue alteration in the dorsal horn and the develop-
ment of hyperalgesia whereas neuronal overexpression 
of VEGFR-2 in mice reduced the sensitivity to paclitaxel-
induced peripheral neuropathy [9]. This outcome seems 
to be related to neuroprotective effects and, accordingly, 
we showed an increase of VEGFR-2 spinal expression 
in oxaliplatin-treated mice that could be considered an 
adaptive response to the damage. On the contrary, the 
acute stimulation of VEGFR-2 does not directly interfere 
with pain.
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Our data show that VEGF-A induces pain by selec-
tively activating the VEGFR-1, which is expressed on 
spinal sensory neurons. A dichotomy between the pro-
algesic VEGFR-1-signaling and the protective VEGFR-
2-signaling is suggested, offering the possibility to relieve 
pain through a target that conserves the neuroprotec-
tive effects of the endogenous VEGF-A. In this view, the 
selective anti-VEGFR-1 mAb D16F7 induced a potent 
pain-relieving effect against nociception triggered by 
VEGF-A or PlGF-2, as well as against neuropathic pain 
evoked by the neurotoxic adverse reactions of different 
anticancer drugs like oxaliplatin, paclitaxel and vincris-
tine. In addition, the pain-relieving effect of D16F7 was 
demonstrated after local (i.t.) and systemic (i.p.) adminis-
tration. D16F7 mAb is able to inhibit VEGFR-1 homodi-
merization, auto-phosphorylation and downstream 
signal transduction [33–35] and down-modulates mem-
brane receptor signalling without affecting VEGF-A or 
PlGF binding [32, 33]. Indeed, D16F7 mAb interacts with 
a receptor site corresponding to amino acids 149–161 of 
human VEGFR-1, which is different from that involved in 
VEGF-A or PlGF binding [33, 78, 79].
CIN is one of the most common adverse events of sev-
eral first-line chemotherapeutic agents, affecting several 
million patients worldwide each year and reducing the 
benefits of effective anticancer therapies in the long-term 
outcome. It is not possible to predict which patients will 
develop symptoms and when  the latter will occurr dur-
ing the chemotherapy course. Moreover, pain and sen-
sory abnormalities may persist for months, or even years 
after the cessation of chemotherapy [80, 81]. The man-
agement of chemotherapy-induced neuropathy is a sig-
nificant challenge and there are no drugs approved to 
prevent or alleviate CIN [3]. In this scenario, VEGF-A is 
candidate to be a possible plasmatic biomarker [4] strictly 
related to pain and the selective blockade of VEGFR-1 is 
proposed as a theoretically ideal strategy to relieve neu-
ropathic hypersensitivity. D16F7 is effective and potent 
against pain induced by several neurotoxic anticancer 
drugs; it is active by a systemic route of administration 
that allows to reach therapeutic concentrations of the 
mAb also at the CNS level, as demonstrated by its anti-
tumor efficacy in orthotopic preclinical models of glio-
blastoma [35]. Thus, D16F7 possesses a double effective 
profile that could be evaluated in the future in tumour-
bearing mouse models of CIN; this would allow to over-
come  the current limitations of this research study that 
was conducted in animals without cancer. Finally, D16F7 
offers the safety qualities requested for the pharmaco-
logical treatment of cancer patients in the presence of a 
possible co-treatment with chemotherapy. The VEGFR-1 
target is mostly involved in pathological processes rather 
than in physiological conditions [32] and in preclinical 
in  vivo studies repeated dosing schedules of the anti-
VEGFR-1 D16F7 did not cause significant adverse effects, 
both as single agent or in combination with immune 
checkpoint inhibitors [28, 33, 35, 36]. Interestingly, due 
to the non-competitive antagonism at the membrane 
receptor level, D16F7 does not interfere with ligand bind-
ing and with the decoy function of soluble VEGFR-1, 
represented by shorter receptor forms lacking the trans-
membrane and intracellular regions. Soluble VEGFR-1 
is released in the extra-cellular matrix and is capable of 
sequestering PlGF or VEGF-A, preventing their interac-
tion with the membrane receptor [32]. Thus, in the pres-
ence of D16F7, the anti-angiogenic, anti-oedema and 
anti-inflammatory properties of soluble VEGFR-1 would 
be preserved, contributing to the further control of neu-
ropathic pain. The unveiling of the downstream receptor 
signalling involved in the complex pain relieving mecha-
nisms [82, 83] deserves further investigation.
Conclusions
In conclusion, VEGF-A is a pro-nociceptive mol-
ecule that activates neuronal firing and induces pain by 
VEGFR-1 stimulation. Interestingly, VEGF-A increases 
during CIN, and its release from spinal astrocytes plays 
a decisive role in neuropathic pain development. More-
over, the anti-VEGFR-1 mAb D16F7 is suggested as a 
promising candidate for the treatment of CIN, adding 
this property to its previously described antitumor effi-
cacy. The results of this proof of concept study encourage 
further investigation on the most effective therapeutic 
schedule for long-term pain control.
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